In patients with COVID-19, impaired fibrinolysis is secondary to high plasminogen activator inhibitor 1 (PAI-1) levels, a member of the serine protease inhibitor superfamily that blocks the conversion of precursor plasminogen to active plasmin [18,133,134,135]. The gene discussed is SERPINE1; the disease is COVID-19.